Dermatology Times

MARCH 28, 2024

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

Dermatitis 88

Dermatitis Dermatology Treatments 88

Dermatology Times

APRIL 5, 2024

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Dermatitis 87

Dermatitis Treatments 87

The Dermatology Digest

JANUARY 2, 2025

One of the core missions of theInternational League of Dermatological Societies ( ILDS ) is to raise awareness about the burden of skin diseases across the globe.ILDS President Henry Lim, MD, theSenior Vice President of Academic Affairs at the Henry Ford Health System inDetroit, MI, discusses how ILDS atlases on psoriasis, vitiligo,hidradenitis suppurativa,and (..)

Dermatitis 74

Dermatitis Dermatology 74

Dermatology Times

MAY 7, 2024

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

Dermatitis 88

Dermatitis Clinic Treatments 88

Dermatology Times

JUNE 10, 2024

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Dermatitis 74

Dermatitis 74

Dermatology Times

APRIL 12, 2024

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

Dermatitis 85

Dermatitis Treatments Safety Management 85

Dermatology Times

DECEMBER 6, 2024

A study using proteome-wide association techniques identified novel protein biomarkers for atopic dermatitis.

Dermatitis 81

Dermatitis 81

Dermatology Times

JUNE 11, 2024

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Dermatitis 77

Dermatitis 77

Dermatology Times

MAY 30, 2024

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

Dermatitis 74

Dermatitis 74

Dermatology Times

APRIL 18, 2024

Researchers noted that further examination and monitoring for headache disorders in patients with atopic dermatitis may be warranted.

Dermatitis 78

Dermatitis 78

Dermatology Times

NOVEMBER 12, 2023

What are some of the challenges and triumphs in using biologics for atopic dermatitis? Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.

Dermatitis 87

Dermatitis 87

Dermatology Times

JULY 13, 2024

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Dermatitis 78

Dermatitis Innovations 78

Dermatology Times

DECEMBER 11, 2023

A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.

Dermatitis 81

Dermatitis 81

Dermatology Times

FEBRUARY 20, 2025

The panelist discusses how understanding the diverse manifestations of atopic dermatitis enables health care providers to develop personalized treatment approaches for optimal patient outcomes.

Dermatitis 70

Dermatitis Treatments 70

Dermatology Times

JUNE 11, 2024

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

Dermatitis 74

Dermatitis 74

Dermatology Times

OCTOBER 3, 2024

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

Dermatitis 74

Dermatitis Clinic Management Treatments 74

Dermatology Times

NOVEMBER 10, 2023

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.

Dermatitis 78

Dermatitis 78

The Dermatology Digest

JANUARY 21, 2025

Dupilumab (Dupixent, Sanofi & Regeneron) may boost height in kids with severe atopic dermatitis (AD), according to a late-breaking abstract presented at Maui Derm Hawaii 2025. The research, presented by Sonya L. Cyr, PhD, Senior Director of Medical Affairs at Regeneron Pharmaceuticals, received the best poster Akamai Award at the meeting.

Pharmaceutical 74

Pharmaceutical Dermatitis Medical Dermatology 74

Dermatology Times

JANUARY 11, 2024

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

Dermatitis 74

Dermatitis Innovations Treatments 74

Dermatology Times

APRIL 2, 2025

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Dermatitis 59

Dermatitis 59

Dermatology Times

MARCH 4, 2024

Raj Chovatiya, MD, PhD, gives a sneak peek of what to expect in atopic dermatitis education at the 2024 American Academy of Dermatology (AAD) Meeting in San Diego, California March 8-12. Since the last meeting, the AAD has released new guidelines to treat the condition.

Dermatitis 74

Dermatitis Education Dermatology 74

Dermatology Times

MAY 14, 2024

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

Dermatitis 74

Dermatitis Clinic Treatments 74

Dermatology Times

MAY 21, 2024

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Dermatitis 74

Dermatitis Clinic Treatments 74

Dermatology Times

JANUARY 23, 2024

A study explored the prioritization habits of both patients with atopic dermatitis and their caregivers when it comes to treatment.

Dermatitis 78

Dermatitis Management Treatments 78

Dermatology Times

DECEMBER 15, 2023

is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Roflumilast foam 0.3% Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.

Dermatitis 74

Dermatitis 74

Dermatology Times

OCTOBER 31, 2024

Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.

Eczema 74

Eczema Dermatitis Clinic Treatments 74

Dermatology Times

FEBRUARY 17, 2025

Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.

Dermatitis 69

Dermatitis Therapy Treatments 69

Dermatology Times

APRIL 12, 2024

Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences.

Dermatitis 69

Dermatitis Treatments Irritation Management 69

Dermatology Times

JANUARY 16, 2024

The FDA has added efficacy and safety data for patients ages 12 years and older with uncontrolled moderate-to-severe atopic dermatitis with hand and/or foot involvement.

Dermatitis 74

Dermatitis Safety 74

Dermatology Times

DECEMBER 5, 2023

Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.

Dermatitis 78

Dermatitis Dermatology 78

Dermatology Times

OCTOBER 11, 2023

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Dermatitis 81

Dermatitis Sustainability Safety Treatments 81

The Dermatology Digest

DECEMBER 27, 2024

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

Dermatitis 36

Dermatitis Portfolios Pharmaceutical Innovations 36

The Dermatology Digest

APRIL 2, 2025

A Qin-Zhu-Liang-Xue (QZLX) decoction may help improve the symptoms of atopic dermatitis (AD), according to preclinical and clinical studies. QZLX significantly improved AD symptoms, as indicated by reduced SCORing Atopic Dermatitis (SCORAD) and Dermatology Life Quality Index (DLQI) scores, with no serious adverse effects.

Dermatitis 36

Dermatitis Networking Dermatology Ingredients 36

The Dermatology Digest

MARCH 17, 2025

has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

Dermatology Times

JUNE 2, 2024

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

Dermatitis 77

Dermatitis Therapy Treatments 77

Dermatology Times

OCTOBER 27, 2024

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

Dermatitis 53

Dermatitis Treatments Therapy Management 53

The Dermatology Digest

FEBRUARY 12, 2025

There is a high prevalence of skin conditions, such as seborrheic dermatitis, melanoma, bullous pemphigoid, and rosacea among people with PD. Can skin symptoms, odor, and sebum composition help diagnose Parkinson’s disease (PD) earlier than is currently possible?

Sebum 62

Sebum Tools Rosacea Dermatitis 62